Dilated cardiomyopathy (DCM) is a myocardial disease characterized by dilation of the left ventricle or of both ventricles, associated with systolic dysfunction, not sufficiently explained by ischemic heart disease, severe arterial hypertension, primary valvular heart disease, congenital heart disease or other pressure or volume overload conditions capable by themselves of producing the observed remodeling. The modern definition must not be interpreted as a simple geometric description of a dilated heart, because the dilated phenotype often represents the common final outcome of genetic, inflammatory, toxic, metabolic, endocrine, arrhythmic or peripartum injuries that impair the cardiomyocyte’s ability to generate force, transmit tension, maintain calcium homeostasis and withstand chronic mechanical stress.
From an epidemiological perspective, dilated cardiomyopathy is one of the main causes of heart failure with reduced ejection fraction, ventricular arrhythmias, sudden cardiac death and indication for heart transplantation in young and middle-aged patients. Prevalence estimates vary substantially according to diagnostic methods, studied populations and inclusion or exclusion of secondary forms; historical series reported values around 1:2500, whereas more recent analyses and family identification strategies suggest that the true frequency may be higher, up to approximately 1:250 in some estimates. The disease may appear at any age, from fetal life to advanced age, but many non-syndromic forms begin in adulthood between the third and sixth decade. The familial component is clinically relevant: a positive family history, sudden death at a young age, conduction disorders, the need for a pacemaker or defibrillator in relatives and the finding of pathogenic variants in cardiomyopathy genes modify the diagnostic pathway, family surveillance and prognostic assessment.
Dilated cardiomyopathy is not a single disease, but a final cardiac phenotype in which many different causes converge toward the same functional result: the ventricle loses contractile efficiency, progressively increases its volumes, assumes a more spherical geometry and develops elevated filling pressures. The first clinically useful distinction separates forms in which the injury arises from a primary genetic cause from acquired forms, but this separation is often artificial. Many patients have a silent genetic predisposition that becomes manifest after a second insult, such as myocarditis, chronic alcohol exposure, cardiotoxic oncological therapy, pregnancy, persistent tachyarrhythmia or autoimmune disease. For this reason, etiology should not be sought as a single label, but as a combination of predisposition, triggers, biological modifiers and degree of reversibility.
Genetic causes include pathogenic or likely pathogenic variants in genes encoding proteins of the sarcomere, cytoskeleton, nuclear membrane, desmosome, calcium handling system, ion channels and cellular stress response complexes. Among the genes with the most consolidated evidence are TTN, which encodes titin, LMNA, which encodes lamin A/C, BAG3, DES, FLNC, MYH7, PLN, RBM20, SCN5A, TNNC1, TNNT2 and DSP. Truncating variants of TTN are among the most frequent alterations in familial dilated cardiomyopathy and act mainly through sarcomeric insufficiency, vulnerability to mechanical stress and reduced contractile reserve. LMNA variants produce a distinctive phenotype because the fragility of the nuclear envelope alters mechanotransduction, genomic stability, the stretch response and the transcriptional organization of the cardiomyocyte; for this reason, the disease may manifest with atrioventricular block, atrial fibrillation, ventricular tachycardia or sudden death before ventricular dilation becomes marked. FLNC, DSP, PLN and RBM20 variants are particularly important because they may be associated with an arrhythmic profile disproportionate to the reduction in left ventricular ejection fraction (LVEF) alone.
Established acquired causes include viral or immune-mediated myocarditis, Chagas disease due to Trypanosoma cruzi in endemic areas or in migrants from those areas, chronic exposure to high amounts of alcohol, some oncological therapies with cardiovascular toxicity, persistent tachycardia or very frequent ventricular ectopy, peripartum cardiomyopathy, selected nutritional deficiencies, uncontrolled endocrinopathies and systemic inflammatory diseases. Alcohol can injure the cardiomyocyte through direct toxicity of ethanol and acetaldehyde, oxidative stress, mitochondrial dysfunction, altered protein synthesis, apoptosis and interstitial remodeling. Anthracyclines promote mitochondrial injury, production of reactive oxygen species, DNA damage, interference with topoisomerase II beta and cardiomyocyte loss; anti-HER2 therapies may reduce cell survival signals mediated by neuregulin and ErbB receptors, making the myocardium more vulnerable to concomitant stresses. In tachycardia-induced cardiomyopathy, by contrast, the injury arises from a chronically elevated ventricular rate or prolonged electrical dyssynchrony, which consume energy reserve, alter intracellular calcium, reduce filling time and induce potentially reversible dilation after rhythm or rate control.
Myocarditis represents one of the most important pathways toward the dilated phenotype. In the acute phase, injury may result from direct pathogen entry into the cardiomyocyte, cell necrosis, activation of innate immunity, lymphocytic infiltration and cytokine production. If inflammation does not resolve, viral persistence or the post-infectious autoimmune response keeps tissue damage signals, extracellular matrix degradation, replacement fibrosis and microvascular dysfunction active. The transition from myocarditis to inflammatory dilated cardiomyopathy occurs when cardiomyocyte loss and interstitial remodeling exceed the compensatory capacity of the ventricle. In this context, endomyocardial biopsy is not a routine test for all patients, but becomes decisive when recognition of lymphocytic, eosinophilic, giant-cell, granulomatous or virus-negative myocarditis can radically modify treatment.
Peripartum cardiomyopathy lies at the boundary between genetic predisposition, hemodynamic stress, angiogenic imbalance, inflammation and prolactin fragmentation. It manifests toward the end of pregnancy or in the months after delivery with heart failure and reduced systolic function, in the absence of previously known heart disease capable of explaining the condition. The hemodynamic overload of pregnancy, increased metabolic demand, oxidative stress and alterations in vascular signals may unmask genetic vulnerability, particularly in some carriers of truncating TTN variants. Its clinical importance derives from its potential reversibility, but also from the risk of recurrence and worsening in subsequent pregnancies, especially if ventricular function has not completely normalized.
Risk factors are not always autonomous causes, but increase the probability that the phenotype will appear, progress or become clinically evident. Familial clustering of cardiomyopathy, sudden cardiac death, early heart failure or implantable devices in first-degree relatives suggests an inherited basis. Male sex, adulthood, ethnicity, obesity, diabetes mellitus, arterial hypertension not sufficiently severe to explain the condition by itself, alcohol consumption, exposure to cocaine or stimulants, viral infections, autoimmune diseases, chronic kidney disease, hemochromatosis, thyrotoxicosis, severe hypothyroidism, pheochromocytoma, acromegaly, thiamine, selenium or carnitine deficiency and a history of oncological therapy increase the likelihood of myocardial dysfunction or modify its evolution. In a patient with genetic predisposition, these factors may act as amplifiers of injury rather than isolated causes.
The pathogenetic core of dilated cardiomyopathy is loss of cardiomyocyte efficiency. When the sarcomere does not generate adequate force, the cytoskeleton does not correctly transmit tension, the nuclear membrane does not tolerate mechanical stress or the sarcoplasmic reticulum handles calcium poorly, each systole becomes less effective. The ventricle initially responds by increasing end-diastolic volume according to the Frank-Starling mechanism, in order to stretch the fibers and maintain stroke volume. This adaptation is useful only in the early phase. As dilation increases, wall tension rises according to Laplace’s law, energy consumption increases, subendocardial perfusion worsens, the mitral apparatus is stretched and ventricular geometry becomes less favorable to contraction. Ventricular dilation, initially a compensatory mechanism, therefore becomes part of the injury.
At the molecular level, chronic systolic dysfunction activates the sympathetic nervous system (SNS), the renin-angiotensin-aldosterone system (RAAS), vasopressin, endothelin and many inflammatory and profibrotic pathways. Norepinephrine and angiotensin II initially increase blood pressure and contractility, but over time they promote apoptosis, necrosis, maladaptive hypertrophy, oxidative stress, interstitial fibrosis and downregulation of beta-adrenergic receptors. Aldosterone promotes sodium retention, expansion of extracellular volume, myocardial fibrosis and vascular dysfunction. Natriuretic peptides represent a compensatory response to wall overload, but become insufficient when filling pressure rises and renal function worsens. The disease therefore assumes a systemic dimension: heart, kidney, lung, liver, skeletal muscle, neuroendocrine system and microcirculation all participate in the progression of heart failure.
Fibrosis is a central pathophysiological element because it transforms a contractility problem into an unstable mechanical and electrical substrate. Diffuse interstitial fibrosis stiffens the ventricle and increases filling pressures; replacement fibrosis creates areas of slow and heterogeneous conduction, predisposing to ventricular re-entry and ventricular tachycardia. On cardiac magnetic resonance imaging, late gadolinium enhancement (LGE) with a non-ischemic pattern, often mid-wall septal or subepicardial, is an indicator of myocardial injury and has prognostic significance. The presence of LGE helps distinguish the non-ischemic dilated phenotype from post-infarction scar, but above all it signals greater vulnerability to arrhythmias, progression of heart failure and a lower probability of complete reverse remodeling.
Hemodynamic pathophysiology derives from reduced stroke volume and increased filling pressures. When the left ventricle does not empty adequately, end-systolic volume increases, end-diastolic volume increases and pressure is transmitted to the left atrium, pulmonary veins and pulmonary capillary circulation. This gives rise to exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea and pulmonary congestion. Dilation of the mitral annulus and displacement of the papillary muscles produce functional mitral regurgitation, which increases volume overload and accelerates remodeling. When the right ventricle is involved directly or secondarily to post-capillary pulmonary hypertension, systemic congestion, hepatomegaly, dependent edema, ascites, functional tricuspid regurgitation and prognostic worsening appear.
The electrical component is not secondary, but an integral part of the disease. Atrial dilation promotes atrial fibrillation, atrial flutter and loss of effective atrial contraction; ventricular fibrosis promotes complex ventricular ectopy, non-sustained ventricular tachycardia, sustained ventricular tachycardia and sudden death. Conduction disorders, such as left bundle branch block, atrioventricular block or intraventricular conduction delay, may be an expression of the disease or may worsen mechanical dysfunction through dyssynchrony. In LMNA, FLNC, PLN, RBM20 and DSP genotypes, arrhythmic fragility may precede or exceed the apparent severity of systolic dysfunction, which is why prognostic assessment cannot be based only on LVEF.
The clinical presentation of dilated cardiomyopathy is highly variable. Some patients are completely asymptomatic and are identified during an echocardiogram performed for a heart murmur, electrocardiographic abnormalities, family history, sports screening, preoperative evaluation or follow-up after oncological therapy. Others come to clinical attention because of overt heart failure, arrhythmia, syncope, systemic embolism or cardiac arrest. The history must therefore proceed methodically, because the diagnosis does not arise only from the image of a dilated ventricle, but from integration of symptoms, family history, exposures, comorbidities, instrumental investigations and etiological plausibility.
During history taking, the patient may report reduced exercise tolerance, easy fatigability, dyspnea during activities that were previously well tolerated, the need to sleep with several pillows, nighttime episodes of air hunger, dry cough due to pulmonary congestion, rapid weight gain from fluid retention or dependent swelling. Exertional dyspnea is often the symptom that leads to the visit, but it is not always described as such: some patients speak of “shortness of breath”, others of reduced performance, and others of inability to climb stairs or walk uphill. Muscle fatigue results from low cardiac output, impaired peripheral perfusion, deconditioning, anemia, skeletal muscle dysfunction and chronic neuroendocrine activation.
Systemic congestive symptoms suggest right-sided involvement or advanced heart failure. The patient may describe ankle edema that worsens in the evening, abdominal tension, early satiety, nausea, pain or heaviness in the right hypochondrium, reduced diuresis, nocturia and increased abdominal girth. In more advanced phases, involuntary weight loss, sarcopenia, anorexia and cardiac cachexia may appear, signs of a systemic disease in which venous congestion, inflammation, malnutrition and intestinal hypoperfusion progressively reduce the body’s reserves.
Arrhythmic manifestations may be the onset of the disease. Rapid and irregular palpitations suggest atrial fibrillation or supraventricular tachycardia; sudden palpitations, syncope, presyncope or episodes of unexplained loss of consciousness require investigation for ventricular tachycardia, atrioventricular block or significant pauses. Syncope in a patient with dilated cardiomyopathy must never be interpreted as a benign event until proven otherwise, especially if it occurs during exertion, in the supine position, without prodromes, in the presence of LGE, non-sustained ventricular tachycardia, family history of sudden death or suspected high-risk genotype.
Chest pain is not the dominant symptom of dilated cardiomyopathy, but it may be present. It may result from relative subendocardial ischemia due to increased wall tension, reduced coronary reserve, microvascular dysfunction, myocarditis, pulmonary embolism, concomitant coronary artery disease or associated pericarditis. Precisely because ischemic heart disease is a fundamental differential diagnosis, chest pain must be interpreted with particular caution, integrating age, cardiovascular risk factors, electrocardiographic abnormalities, troponin, echocardiography, coronary imaging and cardiac magnetic resonance imaging.
Family history is part of the clinical examination, not an accessory detail. At least three generations should be reconstructed, searching for heart failure, transplantation, sudden death before 50 years of age, unexplained drownings or accidents, unclear epilepsy, early pacemaker implantation, defibrillator implantation, juvenile atrial fibrillation, cardiomyopathy, skeletal myopathy, muscle weakness, contractures, dystrophies, deafness, neuropathy, metabolic diseases and neonatal death. An apparently idiopathic cardiomyopathy in a single patient may become familial when relatives are questioned correctly or when cardiological screening is performed in first-degree family members.
The history must then explore exposures and reversible conditions. Alcohol consumption should be quantified by duration, dose and pattern; stimulant substances should be investigated directly but without judgment; previous oncological therapies must be documented with type of treatment, cumulative dose when available, mediastinal irradiation, therapeutic combinations and time elapsed since exposure. Recent infectious episodes, fever, pleuritic chest pain, myalgia, autoimmune diseases, sarcoidosis, hemochromatosis, thyroid disorders, recent pregnancy, prolonged hypertension, known tachyarrhythmias, obstructive sleep apnea, nutritional deficiencies, bariatric surgery, malabsorption and travel to or origin from areas endemic for Chagas disease should be sought.
On physical examination, evaluation begins with the general condition. Cold skin, sweating, confusion, oliguria, hypotension, persistent tachycardia, reduced pulse pressure and mottled skin suggest low output or cardiogenic shock. In less acute presentations, elevated heart rate, normal or low blood pressure, pulsus alternans, rapid breathing and reduced oxygen saturation in the presence of pulmonary edema or pleural effusion may be observed. Increased jugular venous pressure is a useful sign of systemic congestion; hepatojugular reflux supports the diagnosis of right-sided overload even when edema is not yet evident.
Chest examination may show bibasal crackles, reduced breath sounds due to pleural effusion, tachypnea and signs of pulmonary edema. Cardiac examination may reveal a laterally and inferiorly displaced apical impulse, a third heart sound from rapid filling in a dilated ventricle, an apical holosystolic murmur due to functional mitral regurgitation, a parasternal murmur from functional tricuspid regurgitation, accentuation of the pulmonary component of the second heart sound in pulmonary hypertension and a gallop rhythm. The presence of an important valvular murmur must always prompt reassessment of whether the valvular disease is the primary cause of dilation or a functional consequence of ventricular remodeling.
Abdominal and peripheral examination completes the hemodynamic assessment. Tender hepatomegaly, ascites, dependent edema, cold skin, reduced muscle mass and signs of malnutrition indicate chronic congestion or advanced disease. In patients with suspected syndromic disease, extracardiac elements may emerge: proximal weakness, winged scapulae, contractures, ptosis, deafness, neuropathy, cataract, skin abnormalities, endocrinopathies or dysmorphic features. These extracardiac signs suggest myopathies, laminopathies, dystrophies, mitochondrial diseases, storage disorders or metabolic forms that may present with a dilated phenotype.
The real clinical sequence is therefore progressive: suspicion arises from symptoms of heart failure, arrhythmias, syncope, family history or incidental finding; physical examination establishes whether the patient is congested, hypoperfused, arrhythmic or relatively stable; the next priority is to document dilation and systolic dysfunction, exclude more common or removable causes and identify features that modify prognosis and treatment. Clinical signs are not sufficient to diagnose dilated cardiomyopathy, but they determine the urgency of investigations and the need for hospitalization, monitoring or immediate treatment.
When the clinical history and physical examination raise suspicion of dilated cardiomyopathy, the diagnostic pathway must answer four questions in logical order: whether systolic dysfunction with ventricular dilation truly exists; whether the dilation is explained by coronary artery disease, hypertension, valvular heart disease, congenital heart disease or hemodynamic overload; whether there is a specific genetic, inflammatory, toxic, metabolic, endocrine, arrhythmic, peripartum or systemic cause; and whether the patient has features that increase the risk of sudden death, heart failure progression or familial involvement. The correct diagnosis is therefore not the simple label “dilated ventricle”, but the most complete possible phenotypic and etiological diagnosis.
First-level investigations include 12-lead electrocardiogram, blood tests, natriuretic peptide measurement, chest radiography when useful in the clinical context and transthoracic echocardiography. The electrocardiogram may show sinus tachycardia, atrial fibrillation, left bundle branch block, atrioventricular conduction disorders, non-ischemic Q waves, nonspecific repolarization abnormalities, low voltages in some phenocopies or signs of overload. A normal electrocardiogram does not exclude the disease, but a clearly abnormal electrocardiogram in an asymptomatic relative may anticipate the appearance of the echocardiographic phenotype.
Laboratory tests are used to assess severity, differential diagnosis and correctable causes. B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) supports the presence of heart failure and helps in follow-up, although it is not specific for dilated cardiomyopathy. Complete blood count, creatinine, estimated glomerular filtration rate, electrolytes, transaminases, bilirubin, albumin, iron profile, ferritin, transferrin saturation, glucose, glycated hemoglobin, lipid profile, thyroid-stimulating hormone (TSH), possibly free thyroxine, C-reactive protein, troponin, creatine kinase, targeted serologies or infectious disease tests, autoimmunity testing when indicated, hemochromatosis assessment, nutritional indices and toxicology tests should be evaluated when the context requires it.
Transthoracic echocardiography is the key initial test because it documents dimensions, volumes, systolic function and hemodynamic consequences. Phenotypic diagnosis requires left ventricular or biventricular dilation associated with reduced systolic function, assessed through LVEF, indexed volumes, longitudinal function, diameters, global and regional kinetics. The echocardiogram must evaluate the right ventricle, atria, valvular apparatuses, functional mitral and tricuspid regurgitation, estimated pulmonary pressure, diastolic function, intracavitary thrombi, pericardial effusion and signs of alternative heart diseases. Global longitudinal strain may detect early dysfunction and monitor patients exposed to cardiotoxic oncological therapies or at-risk relatives, but it does not replace comprehensive volumetric and clinical assessment.
According to the 2023 European Society of Cardiology (ESC) guidelines, cardiomyopathy evaluation must be multiparametric and oriented toward etiological diagnosis. In the absence of a single universal set of official diagnostic criteria applicable to all causes of dilated cardiomyopathy, formulating a coherent phenotypic diagnosis requires integration of the following elements:
Cardiac magnetic resonance imaging is the most important second-level test in most patients, because it precisely measures ventricular volumes and function, characterizes tissue, distinguishes ischemic and non-ischemic patterns, and evaluates edema, hyperemia, necrosis, focal fibrosis and diffuse fibrosis. Cine sequences quantify volumes and LVEF; LGE identifies scar and replacement fibrosis; T1 and T2 mapping and extracellular volume (ECV) help recognize edema, inflammation, infiltration and diffuse fibrosis. A subendocardial or transmural pattern in a coronary territory suggests ischemic etiology; mid-wall septal LGE is frequent in non-ischemic forms; a subepicardial pattern may suggest myocarditis; inferolateral involvement, extracardiac signs or specific clinical combinations may suggest sarcoidosis, dystrophies, desmosomal forms or other phenocopies.
Exclusion of ischemic heart disease is mandatory in patients whose age, symptoms, risk factors or imaging pattern are compatible. The choice between coronary computed tomography and invasive coronary angiography depends on pre-test probability, clinical stability, expected image quality, renal function, presence of chest pain, elevated troponin or regional abnormalities. Coronary artery disease must not be excluded superficially: a patient may have both genetic predisposition and coronary artery disease, and the final diagnosis must establish whether the coronary disease is sufficient to explain ventricular dysfunction or represents a comorbidity.
Rhythm monitoring is necessary because arrhythmic risk may be underestimated by a single visit. Holter monitoring for 24 to 48 hours, prolonged monitoring, external recorders or selected implantable devices allow identification of atrial fibrillation, flutter, supraventricular tachycardia, frequent ventricular ectopy, non-sustained ventricular tachycardia, pauses, atrioventricular block and arrhythmic burden. This step has diagnostic value when tachycardia-induced cardiomyopathy is suspected, prognostic value in genetic forms and therapeutic value because it may indicate ablation, anticoagulation, defibrillator implantation, resynchronization or therapy modification.
Cardiopulmonary exercise testing (CPET) does not by itself establish the diagnosis of dilated cardiomyopathy, but quantifies functional limitation, distinguishes cardiac and respiratory components from deconditioning, and measures peak oxygen consumption, ventilation to carbon dioxide production slope, anaerobic threshold and exercise blood pressure. It is particularly useful in stratifying advanced heart failure, evaluating patients for transplantation or ventricular assist devices, prescribing exercise and following apparently stable patients with reduced functional reserve.
Genetic testing should be considered when the phenotype is not explained by an evident acquired cause, when there is familial clustering, when onset is early, when conduction disorders, ventricular arrhythmias, skeletal muscle disease, suggestive LGE, history of sudden death or features compatible with high-risk genes are present. It must be preceded by genetic counseling, because a positive result may modify management of the proband and relatives, whereas a variant of uncertain significance must not be artificially transformed into a causal diagnosis. Panels should prioritize genes with a robust gene-disease relationship; interpretation requires correlation with phenotype, familial segregation, population frequency, variant type and available functional data.
Endomyocardial biopsy is indicated in selected contexts, not as indiscriminate screening. It is relevant when fulminant or rapidly progressive myocarditis, giant-cell myocarditis, eosinophilic myocarditis, cardiac sarcoidosis, infiltrative disease, specific toxicity, virus-negative inflammatory cardiomyopathy potentially susceptible to immunosuppression, or recent-onset heart failure with malignant ventricular arrhythmias, advanced blocks or lack of response to therapy is suspected. The examination must include histology, immunohistochemistry and molecular search for viral genomes when indicated, because distinction between virus-positive and virus-negative inflammation may change the therapeutic strategy.
The differential diagnosis is broad and must be addressed explicitly. Ischemic heart disease may mimic dilated cardiomyopathy, especially when dysfunction is global or multivessel. Primary valvular diseases, particularly severe mitral or aortic regurgitation, may produce secondary dilation and must be distinguished from functional regurgitation generated by ventricular dilation. Arterial hypertension may cause dysfunction and dilation in the advanced phase, but usually leaves a history of pressure overload and hypertrophic remodeling. Active myocarditis, arrhythmogenic cardiomyopathy with predominant left-sided involvement, noncompaction cardiomyopathy, stress cardiomyopathy, sarcoidosis, amyloidosis in atypical phenotypes, hemochromatosis, mitochondrial diseases, muscular dystrophies, endocrine diseases, oncological toxicity and tachycardia-induced cardiomyopathy must be considered.
Further investigations depend on the initial results. In the presence of elevated ferritin and transferrin saturation, assessment proceeds toward hemochromatosis testing and magnetic resonance imaging with iron evaluation. If systemic signs, lymphadenopathy, conduction blocks or ventricular arrhythmias with suggestive imaging are present, cardiac sarcoidosis is considered with positron emission tomography (PET) or other targeted tests. If geographic origin justifies it, serology for Trypanosoma cruzi is essential. In patients with muscle weakness, elevated creatine kinase or early conduction disorders, neurological assessment and neuromuscular genetic evaluation may be more informative than repetitive additional cardiological tests.
Treatment of dilated cardiomyopathy has three parallel objectives: improving cardiac function and reducing congestion and mortality, removing or controlling the cause when identified, and preventing sudden death, embolism and progression toward advanced heart failure. Therapy cannot be reduced to generic heart failure management, because two patients with the same LVEF may have completely different risks if one has reversible tachycardia-induced cardiomyopathy and the other has an LMNA variant with atrioventricular block and ventricular tachycardia. The correct strategy combines heart failure treatment, etiological therapy, arrhythmic management, devices, rehabilitation, family follow-up and timely assessment of advanced cases.
In patients with heart failure with reduced ejection fraction, the contemporary therapeutic foundation includes an angiotensin receptor-neprilysin inhibitor (ARNI) or, if not tolerated or not indicated, an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), a beta-blocker with evidence in heart failure, a mineralocorticoid receptor antagonist (MRA) and a sodium-glucose cotransporter 2 inhibitor (SGLT2i). These treatments reduce neuroendocrine activation, wall stress, fibrosis, hospitalizations and mortality, promoting reverse remodeling in many patients. Loop diuretics are not mainly prognostic modifiers, but are indispensable for controlling congestion, pulmonary edema, effusions, ascites and peripheral edema.
Titration must be active and not merely symbolic. Blood pressure, heart rate, renal function, potassium, residual congestion and tolerance guide progressive dose increase. In patients with low blood pressure but congestion, indiscriminately reducing prognostic treatments may be harmful; volume, diuretics, rhythm, anemia, iron status and renal function often need to be optimized first. In the presence of iron deficiency, correction with intravenous iron according to guideline indications may improve symptoms, functional capacity and reduce some hospitalizations. Ivabradine may be considered in patients in sinus rhythm with elevated heart rate despite optimized beta-blocker therapy or when further up-titration is not possible. Digoxin may have a selected role in rate control in atrial fibrillation or in persistent symptoms, but requires attention to renal function, interactions and arrhythmic risk.
Etiological treatment may change the natural history. In tachycardia-induced cardiomyopathy, rhythm or rate control is central: cardioversion, ablation of atrial fibrillation or supraventricular tachycardia, ablation of very frequent ventricular ectopy or idiopathic ventricular tachycardia may lead to major recovery of ventricular function. In alcoholic cardiomyopathy, complete abstinence from alcohol is part of treatment, not a generic recommendation. In toxicity from oncological therapies, integrated cardio-oncological management is required, with modulation of anticancer therapy when possible, heart failure treatment and monitoring with biomarkers and imaging. In endocrinopathies, correction of thyrotoxicosis, severe hypothyroidism, pheochromocytoma, acromegaly or metabolic alterations may reduce myocardial load and improve function.
In inflammatory forms, treatment depends on tissue diagnosis and clinical context. Acute myocarditis requires restriction from intense physical activity, treatment of heart failure, arrhythmic monitoring and management of complications. Immunosuppression must not be used empirically in every dilated cardiomyopathy, but may be indicated in specific inflammatory cardiomyopathies, such as giant-cell myocarditis, eosinophilic myocarditis, cardiac sarcoidosis or documented virus-negative immune-mediated myocarditis. In Chagas disease, antiparasitic therapy and cardiological management must be adapted to phase, age, disease burden and arrhythmic risk. In peripartum cardiomyopathy, therapy must take into account pregnancy, breastfeeding, hemodynamic stability and thromboembolic risk; in expert centers, prolactin inhibition with bromocriptine may be considered in selected contexts, always together with adequate thromboembolic assessment.
Prevention of sudden death requires assessment distinct from heart failure therapy alone. The implantable cardioverter-defibrillator (ICD) is indicated for secondary prevention after cardiac arrest or sustained ventricular tachycardia not due to a reversible cause. In primary prevention, the decision considers persistent LVEF, New York Heart Association (NYHA) functional class, duration and quality of optimized therapy, life expectancy, comorbidities, LGE, syncope, non-sustained ventricular tachycardia, family history and genotype. In patients with dilated cardiomyopathy, heart failure symptoms and LVEF ≤35% despite at least three months of optimized therapy, the ICD should be considered to reduce the risk of sudden death. In high-risk genotypes, such as LMNA, FLNC, PLN, RBM20 and DSP, ICD may be appropriate even with LVEF above 35% when additional risk factors are present.
Cardiac resynchronization therapy (CRT) is indicated when systolic dysfunction is associated with significant electrical dyssynchrony, especially left bundle branch block with wide QRS, persistent symptoms and reduced LVEF despite optimized therapy. The rationale is to correct dyssynchronous contraction, reduce functional mitral regurgitation, improve mechanical efficiency and promote reverse remodeling. Benefit is greater in patients with typical left bundle branch block and very prolonged QRS, whereas it is smaller or absent in narrow QRS complexes. In patients who require frequent ventricular pacing, physiological pacing strategies or resynchronization may prevent worsening caused by pacing-induced dyssynchrony.
Atrial fibrillation must be managed carefully because it worsens ventricular filling, heart rate, symptoms and embolic risk. The choice between rhythm control and rate control depends on arrhythmia duration, atrial size, symptoms, ventricular function, suspicion of tachycardia-induced cardiomyopathy and likelihood of maintaining sinus rhythm. Atrial fibrillation ablation may be useful in selected patients with heart failure and a suspected significant arrhythmic component. Anticoagulation is indicated according to thromboembolic risk in atrial fibrillation and in other specific situations; in patients in sinus rhythm it is not automatic, but should be considered in the presence of ventricular thrombus, previous embolism or high-risk conditions.
Advanced heart failure requires early referral to a dedicated center. Repeated hospitalizations, increasing need for diuretics, hypotension preventing prognostic therapy, hyponatremia, worsening renal function, low output, reduced peak oxygen consumption, recurrent arrhythmias, cachexia, pulmonary hypertension and exercise intolerance indicate an unfavorable trajectory. In these patients, left ventricular assist device, heart transplantation, temporary mechanical support in acute phases, integrated palliative care and shared planning must be evaluated. Late referral reduces options, because organ damage, irreversible pulmonary hypertension, frailty or malnutrition may make the patient unsuitable for candidacy.
Lifestyle is part of therapy but must be individualized. Regular low- or moderate-intensity physical exercise, preferably in cardiac rehabilitation programs, improves functional capacity and quality of life in stable patients. Intense competitive activity must be assessed case by case, especially in the presence of arrhythmic genotypes, LGE, ventricular tachycardia, syncope or significant dysfunction. Weight control, therapeutic adherence, appropriate vaccinations, salt reduction in congested patients, elimination of alcohol in suspected alcoholic cardiomyopathy, avoidance of cocaine and stimulants, treatment of sleep apnea, control of diabetes, blood pressure and kidney disease are important. In women of childbearing age, preconception counseling is mandatory when LVEF is reduced, previous peripartum cardiomyopathy is present or a relevant genetic variant is identified.
Prognosis is extremely heterogeneous. Some patients, especially those with tachycardia-induced cardiomyopathy, alcoholic cardiomyopathy after abstinence, peripartum cardiomyopathy or myocarditis with recovery, may achieve marked reverse remodeling and normalization of LVEF. Others maintain stable chronic dysfunction. A proportion progress toward advanced heart failure, malignant arrhythmias or transplantation. Unfavorable prognostic factors include very reduced LVEF, severe dilation, right ventricular involvement, advanced NYHA class, persistently elevated NT-proBNP, hyponatremia, renal insufficiency, hypotension, extensive LGE, non-sustained or sustained ventricular tachycardia, syncope, atrial fibrillation, significant mitral regurgitation, pulmonary hypertension, failure of reverse remodeling after therapy, high-risk genotypes and family history of sudden death. Improvement in LVEF does not automatically justify withdrawal of therapy, because clinical remission may not coincide with biological cure and treatment withdrawal may lead to recurrence of dysfunction.
The most frequent complication structurally linked to dilated cardiomyopathy is chronic heart failure. It arises from the combination of low contractile efficiency, increased filling pressures, functional mitral regurgitation, neuroendocrine activation, hydrosaline retention and progressive remodeling. The patient may alternate phases of stability with exacerbations precipitated by infections, arrhythmias, poor adherence, excessive salt intake, ischemia, anemia, renal insufficiency, hyperthyroidism, pulmonary embolism or treatments that promote fluid retention. Each hospitalization for heart failure signals a worsening prognostic trajectory and should prompt complete reassessment of therapy, rhythm, residual congestion and possible candidacy for advanced strategies.
Acute heart failure and cardiogenic shock represent the most severe form of hemodynamic deterioration. They may appear at onset, after fulminant myocarditis, rapid arrhythmia, therapy withdrawal, sudden progression or functional mechanical complications. Low output reduces renal, cerebral, hepatic and peripheral perfusion; pulmonary congestion impairs respiratory gas exchange; adrenergic activation temporarily maintains blood pressure but increases myocardial oxygen consumption and arrhythmic risk. In these cases, intensive monitoring, ventilatory support when necessary, diuretic or vasoactive therapy, correction of the precipitating cause and timely evaluation of mechanical circulatory support are required if response is insufficient.
Ventricular arrhythmias are a central complication because they may cause syncope, shock, cardiac arrest and sudden death. The substrate derives from fibrosis, wall stretch, electrical heterogeneity, ion channel alterations, relative subendocardial ischemia, hypokalemia, hypomagnesemia, adrenergic hyperactivation and specific arrhythmic genotypes. Non-sustained ventricular tachycardia may be a risk marker, whereas sustained ventricular tachycardia and ventricular fibrillation require secondary prevention. Sudden death may also occur in patients who are not severely symptomatic, which is why stratification must include imaging, genetics, rhythm and family history, not only functional class.
Atrial fibrillation and other supraventricular tachyarrhythmias worsen symptoms and prognosis because they reduce the atrial contribution to filling, increase ventricular rate, promote congestion and increase embolic risk. In a dilated ventricle, even a moderately elevated but persistent rate may prevent functional recovery. Atrial fibrillation may be a consequence of atrial dilation due to elevated filling pressures, but it may also become a cause or cofactor of ventricular dysfunction. Distinguishing arrhythmia as an effect from arrhythmia as a driver of cardiomyopathy is often possible only by observing recovery after effective rhythm or rate control.
Conduction disorders are particularly important in genetic forms. Atrioventricular block, bundle branch block, early need for pacemaker implantation and progressive conduction slowing should raise suspicion of laminopathy or other high-arrhythmic-risk forms. Chronic right ventricular pacing may worsen dyssynchrony and aggravate systolic dysfunction, so device choice must consider the risk of frequent pacing, need for defibrillation and possible benefit from resynchronization. In patients with high-risk genotypes, implantation of a simple pacemaker without assessment of ventricular tachyarrhythmia risk may leave the most dangerous complication unprotected.
Thromboembolic complications derive from intracavitary stasis, ventricular dilation, low LVEF, atrial fibrillation, endothelial dysfunction and sometimes an inflammatory or peripartum state. Left ventricular thrombus may form especially when function is very depressed, the apex is dyskinetic or areas of slow flow are present. Emboli may involve the brain, kidneys, spleen, limbs or mesenteric circulation. Prevention requires anticoagulation when indicated, echocardiographic or magnetic resonance search for thrombus in high-risk patients and control of the factors that maintain stasis and arrhythmia.
Functional mitral regurgitation is a frequent consequence of ventricular remodeling. Annular dilation, lateral and apical displacement of the papillary muscles, leaflet tethering and reduced systolic closing force prevent valvular coaptation. Functional mitral regurgitation increases the volume returning to the left atrium, worsens pulmonary congestion, promotes atrial dilation and atrial fibrillation, reduces forward stroke volume and feeds further ventricular dilation. In selected patients, after optimized therapy and anatomical evaluation, transcatheter or surgical correction may be considered if regurgitation remains significant and contributes to symptoms.
Right ventricular involvement and pulmonary hypertension are complications of major prognostic importance. The right ventricle may be affected by the same myocardial disease or may secondarily undergo chronic elevation of pulmonary pressures due to left-sided congestion. When the right ventricle fails, systemic congestion, edema, congestive hepatopathy, ascites, functional tricuspid regurgitation and reduction of left-sided output through ventricular interdependence appear. Advanced pulmonary hypertension may complicate candidacy for heart transplantation if it becomes fixed and non-reversible.
Renal dysfunction and cardiorenal syndrome result from hypoperfusion, renal venous congestion, RAAS activation, necessary use of diuretics, hypotension and comorbidities. Renal worsening limits titration of prognostic treatments, increases the risk of hyperkalemia, promotes persistent congestion and worsens prognosis. The liver may also be involved: chronic congestion, hypoperfusion and low output may cause increased transaminases, cholestasis, coagulopathy, congestive fibrosis and, in advanced cases, clinically relevant hepatic injury.
Cardiac cachexia, sarcopenia and frailty are systemic complications of chronic heart failure. They do not depend only on reduced caloric intake, but on inflammation, neuroendocrine activation, malabsorption from intestinal congestion, muscle hypoperfusion, anabolic resistance and reduced physical activity. Loss of muscle mass reduces functional capacity, increases falls and hospitalizations, makes rehabilitation more difficult and worsens the outcome of advanced procedures. Early recognition allows nutritional and rehabilitation interventions and optimization of congestion.
Familial and reproductive complications are no less important than hemodynamic ones. When cardiomyopathy is genetic, first-degree relatives may be asymptomatic carriers and develop ventricular dysfunction, arrhythmias or conduction disorders over time. Failure to identify the proband as a possible familial case deprives relatives of the possibility of early surveillance. In women with DCM or previous peripartum cardiomyopathy, pregnancy may cause worsening, recurrence or severe heart failure, especially if LVEF has not normalized. Preconception counseling must address maternal risk, fetal risk, inheritance, therapy compatible with pregnancy and reproductive alternatives when appropriate.
Finally, complications of devices and advanced therapies are part of the pathway of the most severe patients. ICD and CRT may cause infections, lead dislodgement, inappropriate shocks, vascular complications or need for revisions; ventricular assist devices may involve bleeding, thrombosis, infections and stroke; transplantation requires chronic immunosuppression, rejection surveillance, infectious prevention and management of metabolic and renal complications. These possibilities do not reduce the value of treatments, but require correct selection, clear information and structured follow-up.